No Data
No Data
KIVA SALES LEADER JOINS PRELUDE TO ACCELERATE EXPANSION ACROSS THE CANNABIS SUPPLY CHAIN
Prelude Therapeutics (PRLD) Gets a Sell From Barclays
JMP Securities Maintains Prelude Therapeutics(PRLD.US) With Buy Rating, Maintains Target Price $7
Buy Rating Affirmed for Prelude Therapeutics on Promising PRT3789 Trial Results and Strong Financial Position
Prelude Therapeutics: Uncertainties in Drug Efficacy and Dosing Prompt Sell Rating
Prelude Therapeutics Says PRT3789 Shows 'Encouraging Signs' in Phase 1 Trial; Shares Fall
No Data
No Data